Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Here's Why Clovis Oncology Inc. Is Losing Ground Today

By Cory Renauer - Oct 19, 2018 at 4:22PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Initial results from an ongoing study failed to excite the crowd at an important medical conference.

What happened

Shares of Clovis Oncology Inc. ( CLVS 9.61% ), an oncology-focused biotech company, fell after investigators presented interim results from a clinical trial with its lead drug, Rubraca. Investors less than thrilled with comments from management on the results pushed the stock 12% lower as of 3:55 p.m. EDT on Friday.

So what

This April, Rubraca earned full approval for the maintenance treatment of ovarian cancer. Clovis's lead drug competes with Zejula from Tesaro and Lynparza from AstraZeneca for this patient group, which is why investors were looking forward to today's presentation of prostate cancer data.

Tired-looking person holding a downward-sloping arrow

Image source: Getty Images.

Around 13% of prostate cancer patients harbor a genetic mutation called an ATM alteration, and investors had hoped Rubraca would outperform for this group. Today's loss is largely due to disappointing comments made by Clovis CEO Patrick Mahaffy in an interview with Vantage during the European Society for Medical Oncology meeting. In a nutshell, it doesn't look like the drug produced a meaningful difference for ATM-positive patients.

Now what

Although the stock has fallen, the 44% tumor response rate observed among 25 prostate cancer patients who harbor a BRCA mutation is impressive. Clovis previously stated it would seek accelerated approval for treatment of prostate cancer if Rubraca shrank tumors for just 25% of this group, so we can probably expect the company to send an application to the Food and Drug Administration sooner rather than later.

If you're thinking about picking up shares of Clovis Oncology on the dip, you might want to look a little closer. The company lost $179 million in the first half of the year despite selling $42 million worth of Rubraca. If Rubraca sales don't start rocketing higher soon, the company's recent enterprise value of $1.5 billion could fall much further.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Clovis Oncology, Inc. Stock Quote
Clovis Oncology, Inc.
CLVS
$3.08 (9.61%) $0.27

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
633%
 
S&P 500 Returns
140%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/08/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.